Amendment: SEC Form SC 13G/A filed by Apyx Medical Corporation

10/15/24 9:18:53 AM ET

Medical/Dental Instruments

Health Care

Get the next $APYX alert in real time by email

SC 13G/A 1 apyx2.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information statement pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No.2) Apyx Medical Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 03837C106 (CUSIP Number) Date of Event Which Requires Filing of this Statement: September 30, 2024 *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 03837C106 13G 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Royce & Associates, LP 52-2343049 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION New York NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 2,582,490 6 SHARED VOTING POWER 7 SOLE DISPOSITIVE POWER 2,582,490 8 SHARED DISPOSITIVE POWER 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,582,490 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.45% 12 TYPE OF REPORTING PERSON IA CUSIP No. 03837C106 13G Item 1(a) Name of Issuer: Apyx Medical Corporation Item 1(b) Address of Issuer's Principal Executive Offices: Office of the President Buttonwood Advisory Group, Inc. Huntersville, NC 28078 Item 2(a) Name of Persons Filing: Royce & Associates, LP Item 2(b) Address of Principal Business Office, or, if None, Residence: 745 Fifth Avenue, New York, NY 10151 Item 2(c) Citizenship: New York Corporation Item 2(d) Title of Class of Securities: Common Stock Item 2(e) CUSIP Number: 03837C106 Item 3 If this statement is filed pursuant to rules 13d-1(b), or 13d- 2(b), check whether the person filing is a: (a) [ ] Broker or Dealer registered under Section 15 of the Act (b) [ ] Bank as defined in Section 3(a)(6) of the Act (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (d) [ ] Investment Company registered under Section 8 of the Investment Company Act (e) [X] Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 (f) [ ] Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund (g) [ ] Parent Holding Company, in accordance with Rule 13d-1 (b)(ii)(G) (h) [ ] Group CUSIP No. 03837C106 13G Item 4 Ownership The securities reported herein are beneficially owned by one or more registered investment companies or other managed accounts that are investment management clients of Royce & Associates, LP ("RALP"), an indirect majority owned subsidiary of Franklin Resources, Inc.("FRI"). When an investment management contract (including a sub advisory agreement) delegates to RALP investment discretion or voting power over the securities held in the investment advisory accounts that are subject to that agreement, FRI treats RALP as having sole investment discretion or voting authority, as the case may be, unless the agreement specifies otherwise. Accordingly, RALP reports on Schedule 13G that it has sole investment discretion and voting authority over the securities covered by any such investment management agreement, unless otherwise noted in this Item 4. As a result, for purposes of Rule 13d 3 under the Act, RALP may be deemed to be the beneficial owner of the securities reported in this Schedule 13G. Beneficial ownership by investment management subsidiaries and other affiliates of FRI is being reported in conformity with the guidelines articulated by the SEC staff in Release No. 34 39538 (January 12, 1998) relating to organizations, such as FRI, where related entities exercise voting and investment powers over the securities being reported independently from each other. The voting and investment powers held by RALP are exercised independently from FRI (RALP's parent holding company) and from all other investment management subsidiaries of FRI (FRI, its affiliates and investment management subsidiaries other than RALP are, collectively, "FRI affiliates"). Furthermore, internal policies and procedures of RALP and FRI affiliates establish informational barriers that prevent the flow between RALP and the FRI affiliates of information that relates to the voting and investment powers over the securities owned by their respective investment management clients. Consequently, RALP and the FRI affiliates report the securities over which they hold investment and voting power separately from each other for purposes of Section 13 of the Act. Charles B. Johnson and Rupert H. Johnson, Jr. (the "Principal Shareholders") each own in excess of 10% of the outstanding common stock of FRI and are the principal stockholders of FRI. However, because RALP exercises voting and investment powers on behalf of its investment management clients independently of FRI affiliates, beneficial ownership of the securities reported by RALP is not attributed to the Principal Shareholders. RALP disclaims any pecuniary interest in any of the securities reported in this Schedule 13G. In addition, the filing of this Schedule 13G on behalf of RALP should not be construed as an admission that it is, and it disclaims that it is, the beneficial owner, as defined in Rule 13d 3, of any of such securities. Furthermore, RALP believes that it is not a "group" with FRI affiliates, the Principal Shareholders, or their respective affiliates within the meaning of Rule 13d 5 under the Act and that none of them is otherwise required to attribute to any other the beneficial ownership of the securities held by such person or by any persons or entities for whom or for which RALP or the FRI affiliates provide investment management services. (a) Amount Beneficially Owned: 2,582,490 (b) Percent of Class: 7.45% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote 2,582,490 (ii) shared power to vote or to direct the vote __________ (iii) sole power to dispose or to direct the disposition of 2,582,490 (iv) shared power to dispose or to direct the disposition of __________ Item 5 Ownership of Five Percent or Less of a Class. [ ] Item 6 Ownership of More than Five Percent on Behalf of Another Person. NONE Item 7 Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company. NOT APPLICABLE Item 8 Identification and Classification of Members of the Group. NOT APPLICABLE Item 9 Notice of Dissolution of Group. NOT APPLICABLE CUSIP No. 03837C106 13G Item 10 Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to it is true, complete and correct. Date: October 15, 2024 By: Daniel A. O'Byrne Vice President

Get the next $APYX alert in real time by email

Date

Price Target

Rating

Analyst

10/17/2024

Neutral

BTIG Research

7/14/2023

$8.00

Overweight

Stephens

5/20/2022

$12.00

Buy

Lake Street

8/13/2021

$12.00 → $14.00

Market Outperform

JMP Securities

Amendment: SEC Form SC 13G/A filed by Apyx Medical Corporation

Chat with this insight

Recent Analyst Ratings for $APYX

$APYX SEC Filings

Apyx Medical Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 10-Q filed by Apyx Medical Corporation

Apyx Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$APYX Financials

Live finance-specific insights

Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024

Apyx Medical Corporation Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

$APYX Press Releases

Fastest customizable press release news feed in the world

Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024

Renuvion Named #1 Trusted Body Contouring Technology by Doctors*

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Comparing the Use of Renuvion to a Competing Technology Following Liposuction or Body Contouring Procedures

$APYX Leadership Updates

Live Leadership Updates

$APYX Market Insights

Live Market Insights

$APYX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$APYX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Apyx Medical Corporation Announces Board Leadership Transition

Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

Apyx Medical's New "Renewing Lives" Campaign Offers Free Renuvion Treatments to Those in Need

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Apyx Medical Sees FY24 Revenues Of $49.7M-$52.9M Vs. $49.94M Estimate, Representing Decrease Of Approximately 5% Compared To Growth Of Approximately 1% YoY

Chief Financial Officer Hill Matthew C bought $6,030 worth of shares (5,336 units at $1.13), increasing direct ownership by 213% to 7,836 units (SEC Form 4)

SEC Form 4 filed by Director Waldman Lawrence

SEC Form 4 filed by Director Vizirgianakis Stavros G.

Chief Financial Officer Hill Matthew C bought $6,030 worth of shares (5,336 units at $1.13), increasing direct ownership by 213% to 7,836 units (SEC Form 4)

Hill Matthew C bought $5,475 worth of shares (2,500 units at $2.19) (SEC Form 4)

Goodwin Charles D. Ii bought $78,500 worth of shares (50,000 units at $1.57), increasing direct ownership by 125% to 90,000 units (SEC Form 4)

$APYX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Apyx Medical Corporation

Amendment: SEC Form SC 13G/A filed by Apyx Medical Corporation

SEC Form SC 13D/A filed by Apyx Medical Corporation (Amendment)

$APYX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

BTIG Research initiated coverage on Apyx Medical

Stephens initiated coverage on Apyx Medical with a new price target

Lake Street initiated coverage on Apyx Medical with a new price target

Recent Analyst Ratings for
$APYX

$APYX
SEC Filings

$APYX
Financials

$APYX
Press Releases

$APYX
Leadership Updates

$APYX
Market Insights

$APYX
Insider Trading

$APYX
Insider Purchases

$APYX
Large Ownership Changes

$APYX
Analyst Ratings